These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 9620057)

  • 1. Striatal [18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease.
    Ruottinen HM; Rinne JO; Ruotsalainen UH; Bergman JR; Oikonen VJ; Haaparanta MT; Solin OH; Laihinen AO; Rinne UK
    J Neural Transm Park Dis Dement Sect; 1995; 10(2-3):91-106. PubMed ID: 9620057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction.
    Ruottinen HM; Rinne JO; Oikonen VJ; Bergman JR; Haaparanta MT; Solin OH; Ruotsalainen UH; Rinne UK
    Synapse; 1997 Dec; 27(4):336-46. PubMed ID: 9372556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease.
    Sawle GV; Burn DJ; Morrish PK; Lammertsma AA; Snow BJ; Luthra S; Osman S; Brooks DJ
    Neurology; 1994 Jul; 44(7):1292-7. PubMed ID: 8035933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis.
    Ishikawa T; Dhawan V; Chaly T; Robeson W; Belakhlef A; Mandel F; Dahl R; Margouleff C; Eidelberg D
    J Cereb Blood Flow Metab; 1996 Sep; 16(5):854-63. PubMed ID: 8784230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of response to COMT inhibition in FDOPA PET in advanced Parkinson's disease requires prolonged imaging.
    Ruottinen HM; Niinivirta M; Bergman J; Oikonen V; Solin O; Eskola O; Eronen E; Sonninen P; Rinne UK
    Synapse; 2001 Apr; 40(1):19-26. PubMed ID: 11170218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of catechol-O-methyltransferase inhibition on brain uptake of [18F]fluorodopa: implications for compartmental modelling and clinical usefulness.
    Léger G; Gjedde A; Kuwabara H; Guttman M; Cumming P
    Synapse; 1998 Dec; 30(4):351-61. PubMed ID: 9826227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebral 6-[18F]fluoro-L-DOPA uptake in rhesus monkey: pharmacological influence of aromatic amino acid decarboxylase (AAAD) and catechol-O-methyltransferase (COMT) inhibition.
    Psylla M; Günther I; Antonini A; Vontobel P; Reist HW; Zollinger A; Leenders KL
    Brain Res; 1997 Aug; 767(1):45-54. PubMed ID: 9365014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa.
    Guttman M; Léger G; Reches A; Evans A; Kuwabara H; Cedarbaum JM; Gjedde A
    Mov Disord; 1993 Jul; 8(3):298-304. PubMed ID: 8341294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease.
    Kuwabara H; Cumming P; Yasuhara Y; Léger GC; Guttman M; Diksic M; Evans AC; Gjedde A
    J Nucl Med; 1995 Jul; 36(7):1226-31. PubMed ID: 7790948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of catechol-O-methyl transferase inhibition on peripheral and central metabolism of 6-[18F]fluoro-L-dopa.
    Pauwels T; Dethy S; Goldman S; Monclus M; Luxen A
    Eur J Pharmacol; 1994 May; 257(1-2):53-8. PubMed ID: 8082707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
    Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
    Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positron emission tomography in drug evaluation: influence of three different catechol-O-methyltransferase inhibitors on metabolism of [NCA] 6-[18F]fluoro-L-dopa in rhesus monkey.
    Günther I; Psylla M; Reddy GN; Antonini A; Vontobel P; Reist HW; Zollinger A; Nickles RJ; Beer HF; Schubiger PA
    Nucl Med Biol; 1995 Oct; 22(7):921-7. PubMed ID: 8547890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined FDOPA and 3OMFD PET studies in Parkinson's disease.
    Dhawan V; Ishikawa T; Patlak C; Chaly T; Robeson W; Belakhlef A; Margouleff C; Mandel F; Eidelberg D
    J Nucl Med; 1996 Feb; 37(2):209-16. PubMed ID: 8667046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.
    Najib J
    Clin Ther; 2001 Jun; 23(6):802-32; discussion 771. PubMed ID: 11440283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [18F]-6-fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR-462).
    Laihinen A; Rinne JO; Rinne UK; Haaparanta M; Ruotsalainen U; Bergman J; Solin O
    Neurology; 1992 Jan; 42(1):199-203. PubMed ID: 1734304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data.
    Sawle GV; Playford ED; Burn DJ; Cunningham VJ; Brooks DJ
    Arch Neurol; 1994 Mar; 51(3):237-43. PubMed ID: 8129633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone.
    Nissinen E; Lindén IB; Schultz E; Pohto P
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Sep; 346(3):262-6. PubMed ID: 1407012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls.
    Jokinen P; Helenius H; Rauhala E; Brück A; Eskola O; Rinne JO
    J Nucl Med; 2009 Jun; 50(6):893-9. PubMed ID: 19443601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 6-[18F]fluoro-L-dihydroxyphenylalanine metabolism and positron emission tomography after catechol-O-methyltransferase inhibition in normal and hemiparkinsonian monkeys.
    Miletich RS; Comi G; Bankiewicz K; Plunkett R; Adams R; Di Chiro G; Kopin IJ
    Brain Res; 1993 Oct; 626(1-2):1-13. PubMed ID: 8281420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rate of 6-[18F]fluorodopa uptake decline in striatal subregions in Parkinson's disease.
    Gallagher CL; Oakes TR; Johnson SC; Chung MK; Holden JE; Bendlin BB; McLaren DG; Xu G; Nickles RJ; Pyzalski R; DeJesus O; Brown WD
    Mov Disord; 2011 Mar; 26(4):614-20. PubMed ID: 21449008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.